QQ客服 官方微博 反馈留言

	A randomized, open-label, multicentre, parallel-controlled study comparing the efficacy and safety of biphasic insulin aspart 30 plus metformin with biphasic insulin aspart 30 monotherapy for type 2 diabetes patients inadequately controlled with oral antidiabetic drugs: The merit study
	Guo, Lixin; Chen, Li; Chang, Baocheng; Yang, Liyong; Liu, Yu; Feng, Bo
刊名	DIABETES OBESITY & METABOLISM
	2018
卷号	20期号:12页码:2740-2747
关键词	antidiabetic drug clinical trial insulin therapy metformin type 2 diabetes
DOI	10.1111/dom.13454
URL标识	查看原文
公开日期	[db:dc_date_available]
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/4571910
专题	山东大学
作者单位	1.Beijing Hosp, Dept Endocrinol, Natl Ctr Gerontol, 1 Dahua Rd, Beijing 100730, Peoples R China. 2.Shandong Univ, Dept Endocrin
推荐引用方式 GB/T 7714	Guo, Lixin,Chen, Li,Chang, Baocheng,et al. A randomized, open-label, multicentre, parallel-controlled study comparing the efficacy and safety of biphasic insulin aspart 30 plus metformin with biphasic insulin aspart 30 monotherapy for type 2 diabetes patients inadequately controlled with oral antidiabetic drugs: The merit study[J]. DIABETES OBESITY & METABOLISM,2018,20(12):2740-2747.
APA	Guo, Lixin,Chen, Li,Chang, Baocheng,Yang, Liyong,Liu, Yu,&Feng, Bo.(2018).A randomized, open-label, multicentre, parallel-controlled study comparing the efficacy and safety of biphasic insulin aspart 30 plus metformin with biphasic insulin aspart 30 monotherapy for type 2 diabetes patients inadequately controlled with oral antidiabetic drugs: The merit study.DIABETES OBESITY & METABOLISM,20(12),2740-2747.
MLA	Guo, Lixin,et al."A randomized, open-label, multicentre, parallel-controlled study comparing the efficacy and safety of biphasic insulin aspart 30 plus metformin with biphasic insulin aspart 30 monotherapy for type 2 diabetes patients inadequately controlled with oral antidiabetic drugs: The merit study".DIABETES OBESITY & METABOLISM 20.12(2018):2740-2747.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。